Rubric Capital Management LP Akebia Therapeutics, Inc. Transaction History

Rubric Capital Management LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 13, 2019	SELL	$4.1 - $8.05 $2.48 Million - $4.87 Million	-604,481 Closed	0 $0
Q1 2019 May 10, 2019	SELL	$5.41 - $8.73 $2.52 Million - $4.06 Million	-465,614 Reduced 43.51%	604,481 $4.95 Million
Q4 2018 Feb 13, 2019	BUY	$5.39 - $9.15 $4.14 Million - $7.02 Million	767,364 Added 253.48%	1,070,095 $5.92 Million
Q3 2018 Nov 13, 2018	BUY	$7.44 - $10.65 $2.25 Million - $3.22 Million	302,731 New	302,731 $2.67 Million

120

54.9M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $438M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Rubric Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rubric Capital Management LP with notifications on news.